Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6QOVN)

Drug Name
HKI-272 Drug Info
Synonyms Neratinib (ERBB2 inhibitor)
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
9915743
ChEBI ID
CHEBI:61397
CAS Number
CAS 698387-09-6
TTD Drug ID
DM6QOVN
INTEDE Drug ID
DR1887
ACDINA Drug ID
D00463

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [9]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [10]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [11]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [12]
NERATINIB MALEATE DMEDU7B HER2/NEU overexpressing breast cancer 2C60-2C65 Approved [13]
Margetuximab DMKEY6S HER2-positive breast cancer 2C60-2C65 Approved [14]
Trastuzumab DMZQOUX Breast cancer 2C60-2C65 Approved [15]
Tucatinib DMBESUA HER2-positive breast cancer 2C60-2C65 Approved [16]
Pertuzumab DMHJV0X Adrenal gland neoplasm Approved [17]
Masoprocol DMMVNZ0 Prostate cancer 2C82.0 Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Epidermal growth factor receptor (EGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [19]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [9]
Gefitinib DM15F0X Colon adenocarcinoma Approved [20]
Erlotinib DMCMBHA Adrenal gland neoplasm Approved [21]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [4]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [22]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [11]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [23]
Epidermal growth factor DMVONE6 Vulnerary ND56.Z Approved [22]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [12]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [7]
Gefitinib DM15F0X Colon adenocarcinoma Approved [61]
Erlotinib DMCMBHA Adrenal gland neoplasm Approved [62]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [63]
Gemcitabine DMSE3I7 Anterior urethra cancer Approved [64]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [65]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [66]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [67]
Selenium DM25CGV N. A. N. A. Approved [68]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [69]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [24]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [25]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [26]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [27]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [28]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [4]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [29]
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [30]
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [31]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting ERBB2 messenger RNA (HER2 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-690514 DMX302C Chronic pain MG30 Phase 2 [33]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [34]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [34]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [34]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [35]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [34]
PMID24915291C38 DMBXT9J Discovery agent N.A. Investigative [36]
Geldanamycin-estradiol hybrid DMUSJ96 Discovery agent N.A. Investigative [37]
CL-387785 DMLKFZC Discovery agent N.A. Investigative [38]
HDS-029 DMLRUVA Discovery agent N.A. Investigative [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [39]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [40]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [41]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [42]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [43]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [44]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [45]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [46]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [40]
Verapamil DMA7PEW Angina pectoris BA40 Approved [47]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bile salt export pump (ABCB11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [48]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [49]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [49]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [50]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [48]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [49]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [51]
Gefitinib DM15F0X Colon adenocarcinoma Approved [48]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [6]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Colchicine DM2POTE Acute gout flare FA25.0 Approved [52]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [53]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [54]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [55]
Vinblastine DM5TVS3 Advanced cancer 2A00-2F9Z Approved [52]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [56]
Testosterone DM7HUNW Hot flushes GA30 Approved [57]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [58]
Ibrutinib DMHZCPO Mantle cell lymphoma 2A85.5 Approved [59]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [60]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [2]
ERBB2 messenger RNA (HER2 mRNA) TTR5TV4 ERBB2_HUMAN Inhibitor [3]
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Inhibitor [4]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [6]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Gene/Protein Processing [7]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) OT9RDS3H IKKB_HUMAN Gene/Protein Processing [8]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021154)
2 Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
3 Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.
4 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
5 Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):947-57.
6 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
7 Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J Med Chem. 2011 Mar 10;54(5):1347-55. doi: 10.1021/jm101396q. Epub 2011 Feb 15.
8 Irreversible EGFR inhibitor EKB-569 targets low-LET -radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma. PLoS One. 2011;6(12):e29705. doi: 10.1371/journal.pone.0029705. Epub 2011 Dec 29.
9 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
11 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
12 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
13 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
15 Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
17 Clinical pipeline report, company report or official report of Roche (2009).
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
19 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
20 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
21 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
22 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
23 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
24 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
25 Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
26 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
27 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
28 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
29 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
30 Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
31 Clinical pipeline report, company report or official report of Exelixis (2011).
32 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
33 Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
34 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
35 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
36 Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
37 Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.
38 Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
39 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
40 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
41 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
42 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
43 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
44 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
45 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
46 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
47 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
48 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
49 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
50 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
51 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
52 Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem. 2006 Oct;99(2):402-15. doi: 10.1111/j.1471-4159.2006.04005.x.
53 Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta. Apoptosis. 2009 Jul;14(7):913-22. doi: 10.1007/s10495-009-0367-1.
54 Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J Immunol. 2007 Feb 15;178(4):2507-16. doi: 10.4049/jimmunol.178.4.2507.
55 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
56 Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. J Biol Chem. 2005 Dec 9;280(49):41047-56. doi: 10.1074/jbc.M503713200. Epub 2005 Sep 30.
57 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
58 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
59 Blockade of oncogenic IB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70. doi: 10.1073/pnas.1411701111. Epub 2014 Jul 21.
60 Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-kappa B and I kappa B kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology. 2005 Mar;146(3):1491-7. doi: 10.1210/en.2004-0809. Epub 2004 Nov 24.
61 Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
62 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
63 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
64 A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
65 Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology. 2007;73(1-2):104-11. doi: 10.1159/000120998. Epub 2008 Mar 13.
66 Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
67 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
68 Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
69 Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.